Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
Portfolio Pulse from
Sandoz has received European Commission approval for Afqlir® (aflibercept), a biosimilar to Eylea®, to treat retinal diseases. This strengthens Sandoz's biosimilar portfolio and reinforces its leadership in the global and European markets.
November 15, 2024 | 6:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sandoz's European Commission approval for Afqlir® enhances its biosimilar portfolio, potentially increasing market share and revenue in the biosimilar sector.
The approval of Afqlir® by the European Commission is a significant regulatory milestone for Sandoz, likely to enhance its market position in the biosimilar sector. This could lead to increased revenue and market share, positively impacting SDZNY's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80